Editing Idiopathic intracranial hypertension (section)

===Venous sinus stenting===
Venous sinus stenoses leading to venous hypertension appear to play a significant part in relation to raised [[Intracranial pressure|ICP]], and stenting of a [[transverse sinus]] may resolve venous hypertension, leading to improved [[Cerebrospinal fluid|CSF]] resorption, decreased ICP, cure of papilledema and other symptoms of IIH.<ref name="Ahmed">{{cite journal|last1=Ahmed|first1=RM|last2=Wilkinson|first2=M|last3=Parker|first3=GD|last4=Thurtell|first4=MJ|last5=Macdonald|first5=J|last6=McCluskey|first6=PJ|last7=Allan|first7=R|last8=Dunne|first8=V|last9=Hanlon|first9=M|last10=Owler|first10=BK|last11=Halmagyi|first11=GM|title=Transverse sinus stenting for idiopathic intracranial hypertension: a review of 52 patients and of model predictions.|journal=AJNR. American Journal of Neuroradiology|date=Sep 2011|volume=32|issue=8|pages=1408–14|pmid=21799038|doi=10.3174/ajnr.a2575|pmc=7964366|doi-access=free}}</ref>

A self-expanding metal stent is permanently deployed within the dominant [[transverse sinus]] across the stenosis under general anaesthesia. In general, people are discharged the next day. People require double antiplatelet therapy for a period of up to 3 months after the procedure and aspirin therapy for up to 1 year.

In a systematic analysis of 19 studies with 207 cases, there was an 87% improvement in overall symptom rate and 90% cure rate for treatment of papilledema. Major complications only occurred in 3/207 people (1.4%).<ref>{{cite journal|last1=Teleb|first1=MS|last2=Cziep|first2=ME|last3=Lazzaro|first3=MA|last4=Gheith|first4=A|last5=Asif|first5=K|last6=Remler|first6=B|last7=Zaidat|first7=OO|title=Idiopathic Intracranial Hypertension. A Systematic Analysis of Transverse Sinus Stenting.|journal=Interventional Neurology|date=2013|volume=2|issue=3|pages=132–143|pmid=24999351|doi=10.1159/000357503|pmc=4080637}}</ref> In the largest single series of transverse sinus stenting there was an 11% rate of recurrence after one stent, requiring further stenting.<ref name=Ahmed/>

Due to the permanence of the stent and small but definite risk of complications, most experts will recommend that person with IIH must have papilledema and have failed medical therapy or are intolerant to medication before stenting is undertaken.